NCT03742245 2026-03-16
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT01297764 2026-02-19
QUAD
Hackensack Meridian Health
Phase 1/2 Active not recruiting
NCT03842696 2026-01-27
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT01087554 2026-01-16
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02638090 2025-12-22
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT02553460 2025-12-10
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT03117751 2025-12-05
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2/3 Active not recruiting
NCT03150329 2025-09-03
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03843528 2025-08-11
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
Phase 1 Active not recruiting